Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Accounts Payables (2016 - 2025)

Vanda Pharmaceuticals' Accounts Payables history spans 16 years, with the latest figure at $68.3 million for Q4 2025.

  • For Q4 2025, Accounts Payables rose 74.74% year-over-year to $68.3 million; the TTM value through Dec 2025 reached $68.3 million, up 74.74%, while the annual FY2025 figure was $68.3 million, 74.74% up from the prior year.
  • Accounts Payables for Q4 2025 was $68.3 million at Vanda Pharmaceuticals, up from $47.6 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $68.3 million in Q4 2025 and bottomed at $26.1 million in Q1 2021.
  • The 5-year median for Accounts Payables is $39.2 million (2024), against an average of $41.7 million.
  • The largest annual shift saw Accounts Payables surged 96.87% in 2022 before it plummeted 36.44% in 2023.
  • A 5-year view of Accounts Payables shows it stood at $34.4 million in 2021, then soared by 32.27% to $45.6 million in 2022, then fell by 15.57% to $38.5 million in 2023, then rose by 1.63% to $39.1 million in 2024, then surged by 74.74% to $68.3 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Accounts Payables are $68.3 million (Q4 2025), $47.6 million (Q3 2025), and $57.1 million (Q2 2025).